Discover how James van Geelen, founder of Citrini Research, identified key investment opportunities in weight-loss drugs and AI, positioning himself ahead of market trends.
A groundbreaking study reveals that exercise can reduce cancer patients' risk of death by 37% and recurrence by 28%, proving it's even more effective than many drugs. This landmark trial could reshape health guidelines globally.
President Trump faces backlash for pardoning drug dealers while advocating for harsher penalties. The release of Larry Hoover sparks debate over the effectiveness of U.S. drug policy.
Elon Musk bids farewell to the White House after a controversial tenure leading the Doge initiative, aimed at cutting government costs, while Donald Trump praises his 'colossal change'. Despite challenges, Musk vows to continue influencing government efficiency.
The White House is set to fix errors in Secretary Kennedy's 'Make America Healthy Again' report, which faced scrutiny for citing studies that don’t exist. Despite controversies, the report aims to transform public health policy.
A groundbreaking study shows that GLP-1 diabetes drugs may reduce the risk of obesity-related cancers by 7% compared to DPP-4 inhibitors, particularly in women. Discover the implications for diabetes treatment!
The federal trial of Sean 'Diddy' Combs continues with explosive testimonies revealing disturbing details about his alleged abusive behavior, drug use, and sex trafficking charges.
The FDA has approved the first blood test for Alzheimer's, allowing for earlier diagnosis and treatment with existing drugs. This groundbreaking development could significantly impact millions facing cognitive decline.
The FDA has approved the first blood test for Alzheimer's, allowing for earlier treatment with existing drugs. This innovative test measures protein ratios linked to the disease, promising better patient outcomes.
In a surprising move, Lars Fruergaard Jørgensen is stepping down as CEO of Novo Nordisk after years of leading the company through a successful phase in obesity and diabetes medications. As the search for his successor begins, what does this mean for the future of the pharmaceutical giant?
